

Corrigendum

Corrigendum to “Seroprevalence of Human Betaretrovirus Surface Protein Antibodies in Patients with Breast Cancer and Liver Disease”

Guangzhi Zhang,^{1,2} Kiandokht Bashiri,¹ Mark Kneteman,¹ Kevan Cave,¹ Youngkee Hong,¹ John R. Mackey,³ Harvey J. Alter,⁴ and Andrew L. Mason ^{1,5}

¹Center of Excellence for Gastrointestinal Inflammation and Immunity Research, Division of Gastroenterology, University of Alberta, Edmonton AB T6G 2E1, Canada

²National Microbiology Laboratory, Winnipeg MB R3E 3M4, Canada

³Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

⁴Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD 20892, USA

⁵Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB T6G 2E1, Canada

Correspondence should be addressed to Andrew L. Mason; andrew.mason@ualberta.ca

Received 6 November 2020; Accepted 6 November 2020; Published 4 December 2020

Copyright © 2020 Guangzhi Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Seroprevalence of Human Betaretrovirus Surface Protein Antibodies in Patients with Breast Cancer and Liver Disease” [1], a sentence in Section 2.2 was incorrect. The sentence “A serum panel of breast cancer patients ($n = 98$) and age/sex-matched controls ($n = 102$) was obtained from the Alberta Tomorrow Project, a longitudinal study tracking 55,000 adults in Alberta” should be corrected to “A serum panel of breast cancer patients ($n = 98$) and age/sex-matched controls ($n = 102$) was obtained from the breast cancer outpatient clinic Cross Cancer Institute.” The authors also wish to acknowledge an additional funding body. The modified Acknowledgments section is as follows.

Acknowledgments

We thank the Alberta Cancer Foundation, Alberta Innovates Health Solutions, Canadian Institutes for Health Research, and Canadian Liver Foundation for supporting this project as well as Michael Houghton and Michael Sakalian for their assistance. We thank the Canadian Breast Cancer Foundation for supporting this study.

References

- [1] G. Zhang, M. K. KiandokhtBashiri, Kevan Cave et al., “Seroprevalence of human betaretrovirus surface protein antibodies in patients with breast cancer and liver disease,” *Journal of Oncology*, vol. 2020, Article ID 8958192, 9 pages, 2020.